Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

Published:2020-05-05 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Li Emily¹,Donati Simone²,Lindsley Kristina B³,Krzystolik Magdalena G⁴,Virgili Gianni⁵

Affiliation:

1. Transitional Year Residency Program; Signature Healthcare Brockton Hospital; Brockton MA USA

2. Department of Surgical and Morphological Sciences, Section of Ophthalmology; University of Insubria, Varese-Como; Varese Italy

3. Life Sciences, Oncology, & Genomics; IBM Watson Health; Baltimore Maryland USA

4. Department of Ophthalmology, Retina Service; Mass Eye and Ear Infirmary; Providence RI USA

5. Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference156 articles.

1. Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration;Barikian;American Journal of Ophthalmology,2015

2. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial);Menon;Eye,2013

3. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study;Kertes;Ophthalmology,2019

4. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT);Altaweel;Ophthalmology,2015

5. Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice;Chong;Clinical & Experimental Ophthalmology,2017

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Formulation development of thermoresponsive quercetin nanoemulgels and in vitro investigation of their inhibitory activity on vascular endothelial growth factor-A inducing neovascularization from the retinal pigment epithelial cells;Journal of Drug Delivery Science and Technology;2024-10

2. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab;Ophthalmology and Therapy;2024-08-30

3. Factors Affecting Disease Stability After Intravitreal Brolucizumab Injection for Refractory Neovascular Age-Related Macular Degeneration;Ophthalmology and Therapy;2024-08-12

4. Cochrane Corner: Anti-vascular endothelial growth factor biosimilar for macular degeneration;Eye;2024-07-19

5. Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice;Ophthalmology and Therapy;2024-07-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3